155 related articles for article (PubMed ID: 18058468)
1. Macrophage migration inhibitory factor in cancer.
Yasasever V; Camlica H; Duranyildiz D; Oguz H; Tas F; Dalay N
Cancer Invest; 2007 Dec; 25(8):715-9. PubMed ID: 18058468
[TBL] [Abstract][Full Text] [Related]
2. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas.
Lee H; Rhee H; Kang HJ; Kim HS; Min BS; Kim NK; Kim H
Am J Clin Pathol; 2008 May; 129(5):772-9. PubMed ID: 18426738
[TBL] [Abstract][Full Text] [Related]
3. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression.
Muramaki M; Miyake H; Yamada Y; Hara I
Oncol Rep; 2006 Jan; 15(1):253-7. PubMed ID: 16328065
[TBL] [Abstract][Full Text] [Related]
5. Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer.
Xia HH; Yang Y; Chu KM; Gu Q; Zhang YY; He H; Wong WM; Leung SY; Yuen ST; Yuen MF; Chan AO; Wong BC
Cancer; 2009 Dec; 115(23):5441-9. PubMed ID: 19685530
[TBL] [Abstract][Full Text] [Related]
6. Macrophage migration inhibitory factor expression in ovarian cancer.
Agarwal R; Whang DH; Alvero AB; Visintin I; Lai Y; Segal EA; Schwartz P; Ward D; Rutherford T; Mor G
Am J Obstet Gynecol; 2007 Apr; 196(4):348.e1-5. PubMed ID: 17403417
[TBL] [Abstract][Full Text] [Related]
7. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma.
Khan N; Cromer CJ; Campa M; Patz EF
Cancer; 2004 Jul; 101(2):379-84. PubMed ID: 15241837
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients.
Mroczko B; Groblewska M; Wereszczynska-Siemiatkowska U; Kedra B; Konopko M; Szmitkowski M
Clin Chim Acta; 2006 Sep; 371(1-2):143-7. PubMed ID: 16603145
[TBL] [Abstract][Full Text] [Related]
10. [Expression of macrophage migration inhibition factor (MIF) in serum of patients with prostate cancer and its clinical significance].
Tang WM; Gou X; Liu QX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jan; 27(1):97-8. PubMed ID: 21485220
[TBL] [Abstract][Full Text] [Related]
11. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
12. Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris.
Namazi MR; Fallahzadeh MK; Shaghelani H; Kamali-Sarvestani E
Int J Dermatol; 2010 Feb; 49(2):146-8. PubMed ID: 19799642
[TBL] [Abstract][Full Text] [Related]
13. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
14. Macrophage migration inhibitory factor in systemic lupus erythematosus.
Foote A; Briganti EM; Kipen Y; Santos L; Leech M; Morand EF
J Rheumatol; 2004 Feb; 31(2):268-73. PubMed ID: 14760795
[TBL] [Abstract][Full Text] [Related]
15. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer.
Flamini E; Mercatali L; Nanni O; Calistri D; Nunziatini R; Zoli W; Rosetti P; Gardini N; Lattuneddu A; Verdecchia GM; Amadori D
Clin Cancer Res; 2006 Dec; 12(23):6985-8. PubMed ID: 17145818
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
[TBL] [Abstract][Full Text] [Related]
17. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer.
Roessler M; Rollinger W; Palme S; Hagmann ML; Berndt P; Engel AM; Schneidinger B; Pfeffer M; Andres H; Karl J; Bodenmüller H; Rüschoff J; Henkel T; Rohr G; Rossol S; Rösch W; Langen H; Zolg W; Tacke M
Clin Cancer Res; 2005 Sep; 11(18):6550-7. PubMed ID: 16166432
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of tumor-associated growth factor detection in the diagnosis of colorectal carcinoma].
Yang J; Wang D
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1577-9. PubMed ID: 17959542
[TBL] [Abstract][Full Text] [Related]
19. Increased serum levels of macrophage migration inhibitory factor in patients with Kawasaki disease.
Lee TJ; Chun JK; Yeon SI; Shin JS; Kim DS
Scand J Rheumatol; 2007; 36(3):222-5. PubMed ID: 17657678
[TBL] [Abstract][Full Text] [Related]
20. Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Hatate K; Yamashita K; Hirai K; Kumamoto H; Sato T; Ozawa H; Nakamura T; Onozato W; Kokuba Y; Ihara A; Watanabe M
Oncol Rep; 2008 Oct; 20(4):737-43. PubMed ID: 18813812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
